MedKoo product information:

 Dromostanolone propionate

Masteron (dromostanolone propionate, also known as drostanolone propionate) had formerly been a rare drug in the United States and was enjoyed principally by our European friends. This was due to never been produced in great quantity by Syntex and never being marketed in the United States.  It presently is available from various non-pharmaceutical suppliers. Many also make home-prepared injectables from powder provided by various sources.

Masteron is unaffected by the aromatase and 5alpha-reductase enzymes and therefore there are no issues with estrogen or with potentiation (increase of effect) in tissues such as the skin and prostate. In fact, Masteron is somewhat anti-estrogenic due to competing with estradiol at the estrogen receptor, while not itself activating the receptor, and perhaps by likewise competing with testosterone for the binding site of the aromatase enzyme, thus reducing conversion.  Dromostanolone propionate is the chemical name of active ingredient in Masteron. Masteron was a registered trademark of Sarva-Syntex in Belgium and/or other countries prior to cancellation. from http://www.mesomorphosis.com/steroid-profiles/masteron.htm

Masteron (dromostanolone propionate or drostanolone propionate), is a popular steroid among competitive bodybuilders. It is commonly used in contest preparation for many reasons. To begin with, dromostanolone propionate is a derivative of DHT (dihydrotestosterone), and therefore, it will not aromatize into estrogen. Competing bodybuilders find this extremely beneficial because aromatization typically causes excess water retention which may give the muscles a smooth appearance. Another advantage of Masteron is its strong androgenic component. The androgenic effect of this steroid can cause a noticeable improvement in muscle density and hardness which can help the bodybuilder obtain the “ripped” look if his bodyfat percentage is low enough. The androgenic effect is also crucial because it helps to provide sufficient “kick” or “drive” for intense training when an athlete has lowered his caloric intake for contest preparation. Masteron can also be used successfully by bodybuilders preparing for a drug-tested show. The substance dromostanolone propionate is fast acting and quickly broken down. The athlete can therefore use Masteron up to about ten days before a drug test. The average dosage of Masteron is 100 mg injected every other day. It is best to inject Masteron every 2-3 days because it has a short duration of effect. Popular steroids stacked with Masteron include Parabolan (trenbolone hexahydrobencylcarbonate), Winstrol (stanozolol), and oxandrolone. from http://www.steroids.ro/steroid-profiles/masteron.html.

 1: Marinov L, Tsekova V, Koĭnov K, Velikova M, Micheva D. [Drostanolone propionate (masteril) in disseminated breast cancer in women. Immediate results]. Khirurgiia (Sofiia). 1987;40(6):80-6. Bulgarian. PubMed PMID: 2830431.

2: Iwasa Z, Saeki Y, Matsunami N, Yasutomi M. [Diagnosis of minimal breast cancer by diagnostic hormonal treatment]. Gan No Rinsho. 1986 Apr;32(4):345-8. Japanese. PubMed PMID: 2940386.

3: Fujita H, Teller MN, Green S, Kreis W. Effects of 5-fluorouracil and 2 alpha-methyldihydrotestosterone propionate on the growth of human breast carcinoma MCF-7 in vitro. Eur J Cancer Clin Oncol. 1983 Sep;19(9):1231-7. PubMed PMID: 6688585.

4: Teller MN, Stock CC, Bowie M, Chou TC, Budinger JM. Therapy of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas with combinations of 5-fluorouracil and 2 alpha-methyldihydrotestosterone propionate. Cancer Res. 1982 Nov;42(11):4408-12. PubMed PMID: 6812946.

5: Clavel B, Cappelaere JP, Guerin J, Klein T, Pommatau E, Berlie J. [Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both]. Sem Hop. 1982 Sep 23;58(34):1919-23. French. PubMed PMID: 6293073.

6: Pieńkowska F, Paszko Z, Padzik H, Dziadek T. [Relationship between the effects of endocrinological treatment of breast cancer and the presence of estrogen receptor in the cancer tissue]. Nowotwory. 1980 Jan-Mar;30(1):25-35. Polish. PubMed PMID: 6893078.

7: Trams G. Effect of drostanolone propionate on the binding of oestradiol and dihydrotestosterone by normal and malignant target tissues. Eur J Cancer. 1977 Feb;13(2):149-53. PubMed PMID: 576855.

8: Chowdhury MS, Banks AJ, Bond WH, Jones WG, Ward HW. A comparison of drostanolone propionate (Masteril) and nandrolone decanoate (Deca-durabolin) in the treatment of breast carcinoma. Clin Oncol. 1976 Sep;2(3):203-6. PubMed PMID: 1036981.

9: Bennett MB, Helman P, Palmer P. Hormonal therapy of breast cancer with special reference to Masteril therapy. S Afr Med J. 1975 Nov 15;49(49):2036-40. PubMed PMID: 1242823.

10: von Lieven H, Büll U. [The treatment of metastasising mammary carcinoma with drostanolone propionate (masterid) (author's transl)]. MMW Munch Med Wochenschr. 1974 Nov 22;116(47):2043-6. German. PubMed PMID: 4216810.

11: Drings P, Fritsch H, Schmidt-Hermes HJ. [Experiences with Drostanolone-Propionate (Masterid) in metastasizing breast carcinoma]. Ther Ggw. 1972 Apr;111(4):547-8 passim. German. PubMed PMID: 5029717.

12: Seay DG, Bradshaw JD, Nicol NT. Clinical experience with dromostanolone propionate (NSC-12198) in breast carcinoma. Cancer Chemother Rep. 1972 Feb;56(1):89-92. PubMed PMID: 5067664.

13: Nomura Y, Hattori T, Abe Y, Iguchi K. [Long-term combined administration of dromostanolone propionate (Mastisol) and cyclophosphamide (Endoxan) for advanced breast cancer after surgical hormone therapy]. Gan No Rinsho. 1971 Dec;17(12):899-904. Japanese. PubMed PMID: 5172404.

14: Van der Gugten AA. The effect of I-(morpholinomethyl)-4-phtalimido-piperidindione-2,6 and drostanolone propionate on the plasma prolactin concentration of oestrone-treated orchidectomized R-Amsterdam rats. Eur J Cancer. 1971 Dec;7(6):581-2. PubMed PMID: 5172331.

15: Petit JC, Klein T, Rodier D. [Hormonal therapy of advanced breast cancer with drostanolone propionate]. Bull Cancer. 1971 Oct-Dec;58(4):511-22. French. PubMed PMID: 4115657.

16: Poddig-von Riegen S, Notter G. [Treatment of disseminated mammary carcinoma with drostanolone propionate (Masterid). Report on 22 treated cases]. Munch Med Wochenschr. 1971 Apr 30;113(18):695-7. German. PubMed PMID: 5108667.

17: Brown IG. Treatment of disseminated mammary carcinoma with drostanolone propionate. Practitioner. 1970 Sep;205(227):336-7. PubMed PMID: 5536680.

18: Heney NM. Treatment of advanced breast carcinoma with drostanolone propionate. A case report. Bristol Med Chir J. 1970 Jul;85(315):75-6. PubMed PMID: 5536155.

19: Mückter H, Frankus E, Moré E. Experimental investigations with 1-(morpholinomethyl)-4-phthalimido-piperidindione-2, 6 and drostanolone propionate in dimethylbenz-anthracene-induced tumors of Sprague-Dawley rats. Cancer Res. 1970 Feb;30(2):430-8. PubMed PMID: 5458973.

20: Takeuchi S, Yoshida M. [Clinical study of dromostanolone propionate for mastopathy--with special reference to screening of breast cancer]. Saishin Igaku. 1967 May;22(5):1049-54. Japanese. PubMed PMID: 5630583.